28Jan 2025
LDL Cholesterol Study Highlights Lerodalcibep vs Evolocumab

LDL Cholesterol Study Highlights Lerodalcibep vs Evolocumab

Lerodalcibep and evolocumab showed similar LDL cholesterol reductions in 66 patients with homozygous familial hypercholesterolemia. Reductions were –4.9% and –10.3% at 24 weeks, missing the 6% non-inferiority margin. Both drugs were well tolerated, with fewer injection site reactions for lerodalcibep (2%) versus evolocumab (24%).

  • #endo-diabetology

Like

Save

Share